key: cord-0858336-3jjadbba authors: Arlet, Jean-Benoît; de Luna, Gonzalo; Khimoud, Djamal; Odièvre, Marie-Hélène; de Montalembert, Mariane; Joseph, Laure; Chantalat-Auger, Christelle; Flamarion, Edouard; Bartolucci, Pablo; Lionnet, François; Monnier, Sebastien; Guillaumat, Cécile; Santin, Aline title: Prognosis of patients with sickle cell disease and COVID-19: a French experience date: 2020-06-18 journal: Lancet Haematol DOI: 10.1016/s2352-3026(20)30204-0 sha: b3969c61cecbd6e0388d3744f79af841a5567d60 doc_id: 858336 cord_uid: 3jjadbba nan France is the country with the highest prevalence of sickle cell disease in Europe, with more than 26 000 patients diagnosed with the condition in 2018. Most of these patients are of sub-Saharan African origin. 1 Patients with sickle cell disease are thought to be at increased risk of COVID-19 complications. Aside from specific COVID-19-related morbidities, infections in patients with sickle cell disease 2 can provoke painful vaso-occlusive crisis and life-threatening acute chest syndrome. Thus, COVID-19 could be devastating for regions such as Africa or India, where an estimated 8-12 million patients with sickle cell disease live, or in the USA and Brazil, with more than 100 000 patients in each country. 3 Nevertheless, there are currently no data on the outcomes of patients with sickle cell disease and COVID-19. On March 13, 2020, at an early stage of the COVID-19 pandemic in France, we invited all practitioners involved in the management of patients with sickle cell disease to report on all inpatients with sickle cell disease and confirmed COVID-19 by RNA detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from nasal swabs. An email was sent to paediatricians, internists, and haematologists involved in sickle cell disease managment in France by our national consortia -MCGRE (Filière de santé maladies constitutionnelles rares du globule rouge et de l'érythropoïèse) and Laboratory of Excellence GR-Ex network. We prospectively collected data on outcomes in patients with sickle cell disease infected with COVID-19 using a standardised form. We compared the prevalence of intensive care unit (ICU) admission for inpatients with sickle cell disease by age range to that of COVID-19positive inpatients in France during the same period. 4 Data were collected between March 13, 2020, and April 16, 2020. 83 inpatients with sickle cell disease infected by SARS-CoV-2 from 24 centres were enrolled ( of packed red blood cells per patient. Only 3 (20%) of 15 were transfused before ICU admission (1, 2, and 28 days before), and the other 12 were transfused after a median time of 1·5 days (range 0-9) after ICU admission. Two patients were treated with automated exchanges, 6 with simple transfusions, and 7 with exchange transfusions. One man with the SC genotype died 3 days after admission from a pulmonary embolism without transfusion, and a woman with the SS genotype was not transfused; instead she was treated with high-flow oxygen and then recovered. Of note, seven patients were directly admitted to the ICU; the median time to ICU transfer after hospital admission was 2 days (range 0-9). Among patients with the SS/Sβ⁰ genotype, three (25%) of 12 received a transfusion before ICU admission, which was not different from the proportion of transfusions received throughout the stay for the 22 ( Although these data are relatively few, they do not support an effect of transfusions or hydroxyurea for preventing ICU admission for the management of COVID-19 in patients with sickle cell disease. The prevalence of ICU admission was significantly different between patients with sickle cell disease younger than 45 years and those 45 years or older; 9 (13%) of 68 patients with a median age of 28 years (range 0·3-44) versus eight (53%) of 15 patients with a median age of 54 years (45-68), p=0.0017. Compared with all other inpatients who tested positive for COVID-19 with the same age range, a biphasic trend was observed: a lower risk of ICU admission for young adults (15-44 years) with sickle cell disease than those without the condition (13% vs 24% admitted to ICU; odds ratio (OR) 0·44, 95% CI 0·16-0·99; p=0·039) and a higher but nonsignificant risk for older inpatients (45-64 years) with sickle cell disease (50% vs 36%; OR 1·76, 0·53-5·89; p=0·28, table 2). However, these data should be interpreted with caution because of a lack of statistical power to detect differences. A further limitation of this comparison is that the reasons for hospital admission in the patients without sickle cell disease with COVID-19 could be different (eg, respiratory complaints) compared with patients with sickle cell disease, in part because of sickle cell disease-related complications (eg, vasoocclusive crisis). Nevertheless, this bias should affect age groups similarly. Moreover, we confirmed that 30 (71%) of 42 patients with sickle cell disease in this study had findings of COVID-19 pneumonia on chest CT scans. These results suggest that COVID-19, even if potentially severe, does not seem to carry an increased risk of morbidity or mortality in patients with sickle cell disease, as most patients worldwide have the SS/Sβ⁰ genotype and are younger than 45 years. Our findings also suggest that vaso-occlusive crisis can complicate COVID-19 infection, occuring in around half of inpatients with sickle cell disease. The hypothesis of a protective effect against COVID-19 in patients with the SS/Sβ⁰ variant should be explored. Patients with the SS genotype have been shown to have high plasma interferon-α concentrations and their neutrophils showed a clear type I interferon signature. 5 SARS-CoV-2 does not seem to trigger substantial interferon responses ex vivo, which could explain increased viral replication. 6 However, older patients with sickle cell disease should be considered vulnerable to SARS-CoV-2 and should follow guidelines from their respective country to prevent being exposed to it. These patients should also be closely monitored if they become hospitalised becasue of COVID-19. Comparison between adult patients with sickle cell disease of sub-Saharan African origin born in metropolitan France and in sub-Saharan Africa Pandemic influenza A (H1N1) virus infections in children with sickle cell disease Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions COVID-19: epidemiological update of April 9 The proteome of neutrophils in sickle cell disease reveals an unexpected activation of interferon alpha signaling pathway Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 We declare no competing interests.